BACKGROUND: Statins are indicated for prevention of atherosclerotic cardiovascular disease. Metabolism of certain statins involves the cytochrome P450 3A (CYP3A) enzymes, and CYP3A4*22 significantly influences the dose needed for achieving optimal lipid control for atorvastatin, simvastatin, and lovastatin. CYP3A4/5 combined genotype approaches have proved useful in some studies involving CYP3A substrates. We intend to compare a combined genotype analysis to our previously reported single gene CYP3A4 analysis. METHODS: A total of 235 patients receiving stable statin doses were genotyped and grouped by CYP3A4/5 status. RESULTS: The number and demographic composition of the patients categorized into the combined genotype groups were consistent with those reported for other cohorts. Dose requirement was significantly associated with the ordered combined-genotype grouping; median daily doses were nearly 40% greater for CYP3A4/5 intermediate metabolizers compared with poor metabolizers, and median daily doses were nearly double for extensive metabolizers compared with poor metabolizers. The combined-genotype approach, however, did not improve the genotype-dosage correlation p-values when compared with the previously-reported analysis; values changed from 0.129 to 0.166, 0.036 to 0.185, and 0.014 to 0.044 for atorvastatin, simvastatin, and the combined statin analysis, respectively. CONCLUSIONS: The previously-reported single-gene approach was superior for predicting statin dose requirement in this cohort.
BACKGROUND: Statins are indicated for prevention of atherosclerotic cardiovascular disease. Metabolism of certain statins involves the cytochrome P450 3A (CYP3A) enzymes, and CYP3A4*22 significantly influences the dose needed for achieving optimal lipid control for atorvastatin, simvastatin, and lovastatin. CYP3A4/5 combined genotype approaches have proved useful in some studies involving CYP3A substrates. We intend to compare a combined genotype analysis to our previously reported single gene CYP3A4 analysis. METHODS: A total of 235 patients receiving stable statin doses were genotyped and grouped by CYP3A4/5 status. RESULTS: The number and demographic composition of the patients categorized into the combined genotype groups were consistent with those reported for other cohorts. Dose requirement was significantly associated with the ordered combined-genotype grouping; median daily doses were nearly 40% greater for CYP3A4/5 intermediate metabolizers compared with poor metabolizers, and median daily doses were nearly double for extensive metabolizers compared with poor metabolizers. The combined-genotype approach, however, did not improve the genotype-dosage correlation p-values when compared with the previously-reported analysis; values changed from 0.129 to 0.166, 0.036 to 0.185, and 0.014 to 0.044 for atorvastatin, simvastatin, and the combined statin analysis, respectively. CONCLUSIONS: The previously-reported single-gene approach was superior for predicting statin dose requirement in this cohort.
Authors: Marilu Fiegenbaum; Fabiano R da Silveira; Cézar R Van der Sand; Luiz Carlos Van der Sand; Maria E W Ferreira; Renan C Pires; Mara H Hutz Journal: Clin Pharmacol Ther Date: 2005-09-26 Impact factor: 6.875
Authors: Laure Elens; Rachida Bouamar; Dennis A Hesselink; Vincent Haufroid; Teun van Gelder; Ron H N van Schaik Journal: Pharmacogenet Genomics Date: 2012-05 Impact factor: 2.089
Authors: Hong-Guang Xie; Alastair J J Wood; Richard B Kim; C Michael Stein; Grant R Wilkinson Journal: Pharmacogenomics Date: 2004-04 Impact factor: 2.533
Authors: Maria Alice V Willrich; Mario H Hirata; Fabiana D V Genvigir; Simone S Arazi; Ivanise M M Rebecchi; Alice C Rodrigues; Marcia M S Bernik; Egidio L Dorea; Marcelo C Bertolami; André A Faludi; Rosario D C Hirata Journal: Clin Chim Acta Date: 2008-08-05 Impact factor: 3.786
Authors: Thomas P Ahern; Per Damkier; Søren Feddersen; Anders Kjærsgaard; Timothy L Lash; Stephen Hamilton-Dutoit; Cathrine Bredal Lythjohan; Bent Ejlertsen; Peer M Christiansen; Deirdre P Cronin-Fenton Journal: Acta Oncol Date: 2020-04-30 Impact factor: 4.089
Authors: Georgia Ragia; Vana Kolovou; Anna Tavridou; Laure Elens; Alexandros D Tselepis; Moses Elisaf; Ron H N Van Schaik; Genovefa Kolovou; Vangelis G Manolopoulos Journal: Mol Diagn Ther Date: 2014-06 Impact factor: 4.074
Authors: Jessica K Roberts; Chad D Moore; Robert M Ward; Garold S Yost; Christopher A Reilly Journal: J Pharmacol Exp Ther Date: 2013-03-19 Impact factor: 4.030
Authors: Joseph P Kitzmiller; Jasmine A Luzum; Damiano Baldassarre; Ronald M Krauss; Marisa W Medina Journal: Pharmacogenet Genomics Date: 2014-10 Impact factor: 2.089
Authors: Miriam Saiz-Rodríguez; Susana Almenara; Marcos Navares-Gómez; Dolores Ochoa; Manuel Román; Pablo Zubiaur; Dora Koller; María Santos; Gina Mejía; Alberto M Borobia; Cristina Rodríguez-Antona; Francisco Abad-Santos Journal: Biomedicines Date: 2020-04-22